WallStreetZenWallStreetZen

NASDAQ: KPTI
Karyopharm Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

KPTI past revenue growth

How has KPTI's revenue growth performed historically?
Company
-7.03%
Industry
145.22%
Market
17.76%
KPTI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
KPTI's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
KPTI's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

KPTI earnings and revenue history

Current Revenue
$146.0M
Current Earnings
-$143.1M
Current Profit Margin
-98%

KPTI Return on Equity

Current Company
N/A
Current Industry
-63.5%
Current Market
188%

Be the first to know when KPTI announces earnings.

KPTI Return on Assets

Current Company
-50.5%
Current Industry
2.9%
KPTI is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

KPTI Return on Capital Employed

Current Company
-69.58%
Current Industry
19.5%
KPTI's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

KPTI vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
KPTI$146.03M-$118.42M-$143.10M+36.93%N/A
SEER$16.66M-$80.49M-$86.28M+246.19%N/A
OMGA$3.09M-$90.66M-$97.43M+363.53%N/A
AMLX$380.79M$55.39M$49.27M+304.24%N/A
PDSB$0.00-$42.87M-$42.94MN/AN/A
View Top Biotech Stocks

KPTI earnings dates

Next earnings date
May 29, 2024

Karyopharm Therapeutics Earnings & Revenue FAQ

What were KPTI's earnings last quarter?

On Invalid Date, Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 2023 earnings per share (EPS) of -$0.36, up 14.29% year over year. Total Karyopharm Therapeutics earnings for the quarter were -$41.84 million. In the same quarter last year, Karyopharm Therapeutics's earnings per share (EPS) was -$0.42.

If you're new to stock investing, here's how to buy Karyopharm Therapeutics stock.

What was KPTI's earnings growth in the past year?

As of Q2 2024, Karyopharm Therapeutics's earnings has grown year over year. Karyopharm Therapeutics's earnings in the past year totalled -$143.10 million.

What is KPTI's earnings date?

Karyopharm Therapeutics's earnings date is Invalid Date. Add KPTI to your watchlist to be reminded of KPTI's next earnings announcement.

What was KPTI's revenue last quarter?

On Invalid Date, Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 2023 revenue of $33.75 million up 0.5% year over year. In the same quarter last year, Karyopharm Therapeutics's revenue was $33.58 million.

What was KPTI's revenue growth in the past year?

As of Q2 2024, Karyopharm Therapeutics's revenue has grown -7.03% year over year. This is 152.25 percentage points lower than the US Biotechnology industry revenue growth rate of 145.22%. Karyopharm Therapeutics's revenue in the past year totalled $146.03 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.